NCT02386800Active, not recruitingPhase 4
CINC424A2X01B Rollover Protocol
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 279 (actual)
- First submitted
- 6 Mar 2015
- Start date
- 5 Mar 2015
- Primary completion date
- 5 Apr 2032
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Myeloproliferative neoplasms, Chronic myeloid leukaemia, Thalassaemia, Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT02386800
- EU CT number
- 2024-515283-31-00
- EudraCT number
- 2014-003527-22
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 279
- From 5 Mar 2015 to the primary completion date, 5 Apr 2032
- 73 sites in 25 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient has been permanently discontinued from study treatment in the parent study due to any reason.
- Patient's indication is currently approved and reimbursed in the corresponding country for ruxolitinib monotherapy or combination of ruxolitinib and panobinostat.
- Pregnant or nursing (lactating) women.
- Female patients of childbearing potential (e.g. are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment.
- Other protocol-defined Inclusion / Exclusion criteria may apply.
Who the study is looking for
- Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsored clinical study, are receiving either ruxolitinib or combination of ruxolitinib and panobinostat, and fulfilled all of the requirements of the parent protocol.
- Patient is currently benefiting from the treatment with ruxolitinib monotherapy or combination of ruxolitinib and panobinostat, as determined by the investigator
- Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements
- Patient currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with ruxolitinib or combination of ruxolitinib and panobinostat
Age in the registry: 1 month to 100 years · Sex: All · Does not accept healthy volunteers
Sites (73)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.